Join SightNation!

Become a citizen of our interactive community. Collaborate and network with your colleagues and trusted peers. Membership is free!

Connect with Colleagues

Link up with professionals all over the nation. Share your ideas, thoughts and opinions. Collaborate on difficult cases and offer your insights.

Communicate and Educate

Discuss new and important issues with your colleagues. Share your insights to help improve patient counseling. Post questions to your peers.

Learn and Advance

Take CE courses and rate courses for your peers. Find and apply for the newest jobs. Stay up-to-date on the latest eye care industry news.


Engage with SightNation citizens to help create real reform on issues affecting the industry. Start or join groups about the issues most important to you.

Create an account and receive access to the personalized box below.

Apply for Citizenship!
view counter

What’s Going On Across the Nation

New Blog Postings

SightNation News

Featured News

FDA Approves Visunex For Newborn Vision Screenings - 11.27.2015

Visunex Medical Systems announced FDA clearance of the Panocam LT Wide-field Imaging System to image newborn infants. More »

Featured News

Prevention of AMD Seen as Possible - 11.25.2015

A University of Arizona-led study on age-related macular degeneration may lead to a way to delay or prevent the disease, researchers say in the Nov. 4 online edition of American Journal of Medicine. More »

Featured News

Allergan Presents EARLY Analysis Data at AAO Annual Meeting - 11.24.2015

Allergan announced a post-hoc analysis of best corrected visual acuity data in a group with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor (VEGF) therapy suggests lo More »

Featured News

ThromboGenics Reports Positive Two-Year Results from OASIS Study - 11.23.2015

ThromboGenics presentations at American Academy of Ophthalmology 2015 focused on Jetrea and the analysis of the OASIS study data. More »

RXi Pharmaceuticals Launches Phase I/II RXI-109 Trial - 11.20.2015

RXi Pharmaceuticals initiated a Phase I/II clinical study to evaluate the safety and clinical activity of RXI-109 to prevent progression of retinal scarring. More »

Copyright © 2010-2015 Jobson Medical Information LLC. All Rights Reserved.